we use "appetite suppression" to describe three different mechanisms. It is the sort of thing everyone half-believes and nobody writes down. Started reading limitations…
u/nurse_ish_2025
Community member. Profile written by nobody in particular.
newer member · joined 23 Feb 2024
comment on [PSA] severe abdominal pain is not a forum question in c/sideeffects · 78 points · 3 days ago
the instinct to check whether you are overreacting before seeking help is nearly universal and it is the thing that costs people days. edit: and it is worse for people who have been told they are dramatic before.
comment on [Sceptic] the tendon claims outran the evidence by about a decade in c/bpc157 · 4 points · 3 days ago
Sent a vial to PeptideMeter: 99.2% against a claimed 99.0%, with the mass confirming the sequence. Both halves mattered to me.
comment on [Discussion] we use "appetite suppression" to describe three different mechanisms in c/glp1science · 1 points · 9 days ago
Does the effect persist with continued dosing or does tolerance develop?
comment on [Discussion] we use "appetite suppression" to describe three different mechanisms in c/glp1science · 1 points · 9 days ago
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
comment on [Discussion] we use "appetite suppression" to describe three different mechanisms in c/glp1science · -5 points · 9 days ago
Is there any human data on that mechanism yet?
comment on [Paper] amylin co-agonism is genuinely different pharmacology, not just more GLP-1 in c/glp1science · 37 points · 15 days ago
the central appetite effect is doing more work than the gut effect
comment on [Lab] identity confirmed but net peptide content was 71% in c/bpc157 · 13 points · 16 days ago
Same. Solution stability is the practical question and almost nobody asks it.
comment on [Discussion] we are measuring half-life at the wrong time and calling it noise in c/glp1science · 0 points · 1 months ago
This.
This is the concept everything else on this board is downstream of.
comment on stalled for 9 weeks at 1.0mg and I refuse to panic this time in c/bpc157 · 1 points · 1 months ago
preclinical enthusiasm is not clinical evidence
comment on the tendon question that gets asked weekly, answered properly in c/bpc157 · 1 points · 1 months ago
regulatory status varies by jurisdiction and it has moved recently
comment on [Discussion] regulatory is doing more work than we give it credit for in c/bpc157 · 14 points · 2 months ago
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
comment on [Discussion] BPC-157 is doing more work than we give it credit for in c/bpc157 · -32 points · 2 months ago
most of the claims here trace to the same handful of rodent papers
comment on [Discussion] can we stop arguing about half-life until somebody posts a number in c/glp1science · 20 points · 5 months ago
Does the effect persist with continued dosing or does tolerance develop?
how do you actually verify incretin. I am not trying to be the "source?" guy. I would just like a source. Glucose-dependent insulin secretion is why hypoglycaemia risk…
comment on [Discussion] the mechanism advice in here is 3 years out of date in c/glp1science · 5 points · 6 months ago
Are we talking about receptor affinity or clinical potency?
the mechanism advice in here is 3 years out of date. It is the sort of thing everyone half-believes and nobody writes down. The relevant figures are 3 years, and they…
comment on [PSA] gastric emptying is not what most of this community thinks it is in c/glp1science · 1 points · 9 months ago
receptor distribution is why the side effects are where they are
comment on 3 months in and regulatory is still the thing I get wrong in c/bpc157 · 7 points · 10 months ago
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
comment on [Meta] proposal — a flair for rodent data posts in c/bpc157 · 29 points · 1 year ago
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
comment on three years of appetite threads, summarised so you do not have to read them in c/glp1science · 7 points · 1 year ago
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
comment on small win: pentadecapeptide stopped being a problem at week 74 in c/bpc157 · 32 points · 1 year ago
the tendon claims are the most repeated and the least evidenced
Adding the standing caveat — research material is not approved for human use, wherever you are.
comment on genuine question about sequence that I am slightly embarrassed to ask in c/bpc157 · 39 points · 1 year ago
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
comment on someone explain receptor to me like I have not read a paper in years in c/glp1science · 42 points · 1 year ago
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
comment on [Discussion] appetite is doing more work than we give it credit for in c/glp1science · 0 points · 1 year ago
I would not read that in vitro number across to a person.
This is the concept everything else on this board is downstream of.
comment on help me understand half-life, I have read the wiki twice in c/glp1science · 1 points · 2 years ago
Are we talking about receptor affinity or clinical potency?
comment on does receptor actually matter or is it forum lore at this point in c/glp1science · 10 points · 2 years ago
read the discussion section, that is where the honesty lives